Clinical trials: Motor Fluctuations
Parkinson Disease
Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
This is a phase 2 study, randomized, double-blind, placebo-controlled, multicenter study of oral CVN424 at two dose levels (low-dose and high-dose) in Parkinson's disease (PD) patients with motor fluctuations.
- Trial name
- NCT04191577
- Testing
- CVN424 Low Dose, CVN424 High Dose
- Where
- 21 sites in United States
- Volunteers
- 136 people
- Sponsor
- Cerevance Beta, Inc.
Parkinson Disease
OpiCapone Effect on Motor Fluctuations and pAiN
The aim of this study is to investigate the efficacy of 50 mg opicapone when administered with the existing treatment of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI), in Parkinson's disease (PD) patients with…
- Trial name
- OCEAN (NCT04986982)
- Testing
- Opicapone 50 mg
- Where
- United Kingdom
- Volunteers
- 144 people
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease With Motor Fluctuations
Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
- Trial name
- NCT03185481
- Testing
- 1 mg QD to 15 mg QD PF-06649751, 3 mg QD to 15 mg QD PF-06649751, 7 mg QD to 15 mg QD PF-06649751
- Where
- 9 sites in United States
- Volunteers
- 5 people
- Sponsor
- Pfizer
Dyskinesias, Parkinson's Disease
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
Long term safety and efficacy (12 months) of levodopa-carbidopa intestinal gel.
- Conditions
- Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
- Trial name
- NCT00360568
- Testing
- Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube
- Where
- 22 sites in United States, Germany and 1 more
- Volunteers
- 62 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Parkinson's Disease (PD)
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- NCT04380142
- Testing
- ABBV-951, Levodopa/Carbidopa (LD/CD)
- Where
- 76 sites in United States, Australia
- Volunteers
- 174 people
- Sponsor
- AbbVie
Advanced Parkinson's Disease
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.
- Trial name
- NCT00357994
- Testing
- Levodopa carbidopa intestinal gel (LCIG), Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, CADD-Legacy® 1400 ambulatory infusion pump
- Where
- 15 sites in United States, Germany
- Volunteers
- 36 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Parkinson's Disease
A Study of E2007 In Patients With Parkinson's Disease
Phase IIb open-label extension study for patients with Parkinson's Disease. All patients will receive active study drug. The study will involve outpatient visits only.
- Trial name
- NCT00427011
- Testing
- E2007
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Eisai Inc.
Parkinson's Disease
Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients
The purpose of this study is to investigate the tolerability and the effect of BIA 9-1067 at steady-state on the levodopa pharmacokinetics in Parkinson's Disease (PD) patients treated with levodopa/dopa-decarboxylase inhibitor.
- Trial name
- NCT01568047
- Testing
- BIA 9-1067, Levodopa/Carbidopa, Levodopa/Benzerazide
- Where
- 7 sites in Romania, Ukraine
- Volunteers
- 40 people
- Sponsor
- Bial - Portela C S.A.
Idiopathic Parkinson Disease
Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.
Phase 3, international, multicenter, open-label 12 month safety study.
- Trial name
- NCT03051607
- Testing
- Tozadenant
- Where
- 35 sites in United States, Canada and 1 more
- Volunteers
- 66 people
- Sponsor
- Biotie Therapies Inc.